Atrys Business Model Canvas
Unlock Healthcare Diagnostics Business Model Canvas — Ready-to-Use Strategic Blueprint
Unlock Atrys’s full Business Model Canvas to see exactly how the company creates value, scales services, and captures healthcare and diagnostics market share. This concise, actionable canvas breaks down customer segments, revenue streams, partnerships and cost structure—ready in Word and Excel. Purchase the complete file for a practical, ready-to-use strategic blueprint ideal for investors, consultants, and founders.
Partnerships
Hospitals and clinics
Partner with public and private hospitals to integrate diagnostics, imaging and oncology workflows, leveraging Atrys networks expanded in 2024 to deepen clinical ties across Spain and Latin America.
Co-develop care pathways and referral protocols to streamline patient intake and reduce delays between diagnosis and treatment.
Enable integrated data exchange with shared quality metrics and support multi-site coverage to ensure continuity of care across hospital networks.
Academic and research institutions
Collaborate with academic and research institutions on clinical trials, genomics research, and validation studies to access novel biomarkers, advanced imaging protocols, and robust evidence generation. Co-author peer-reviewed publications to strengthen clinical credibility and market acceptance. Leverage 2024 research funding streams such as Horizon Europe and institutional grants to subsidize trials and use shared research infrastructure for scale.
Technology and AI vendors
Form alliances with AI, cloud and cybersecurity providers to scale Atrys platforms, tapping a healthcare AI market that surpassed $20B in 2024 and a global cloud services market above $600B. Integrate best-in-class imaging, pathology and genomics algorithms to raise diagnostic accuracy and throughput. Ensure interoperable, regulatory-grade data pipelines to accelerate product roadmaps and cut time-to-market.
Medical device and pharma companies
Atrys partners with medical device and pharma firms to provide companion diagnostics, theranostics, and treatment-planning tools, supporting biomarker-driven patient selection for trials and commercialization; global companion diagnostics market ~6.3 billion USD in 2024. Co-creation of post-market evidence and RWD programs strengthens regulatory positioning and safety signals while joint commercialization expands distribution and revenue reach.
- Companion diagnostics: co-development
- Biomarker-based patient selection: trial enrichment
- RWD/post-market: evidence generation
- Joint commercialization: channel expansion
Payers and health systems
Atrys partners with payers and health systems to align on value-based care and reimbursement pathways, pilot bundled payments for diagnostics and oncology episodes, and share risk through outcome-based contracts tied to clinical benchmarks while integrating services into payer networks and formularies to improve access.
- Value-based alignment
- Bundled diagnostics/onco pilots
- Outcome-based risk sharing
- Payer network integration
Integrate diagnostics, imaging and oncology across Spain & LATAM in 2024
Partner with public/private hospitals to integrate diagnostics, imaging and oncology workflows, leveraging Atrys network expansion in 2024 across Spain and Latin America.
Co-develop care pathways, referral protocols and shared data exchange to shorten diagnosis-to-treatment times and ensure multi-site continuity.
Alliances with AI/cloud/cybersecurity vendors and pharma/device firms accelerate regulatory-grade algorithms and companion diagnostics; healthcare AI market ~$20B (2024), cloud ~$600B (2024), companion dx ~$6.3B (2024).
| Partner | 2024 metric |
|---|---|
| AI market | $20B |
| Cloud market | $600B |
| Companion dx | $6.3B |
What is included in the product
Detailed Word Document
A comprehensive, pre-written Business Model Canvas for Atrys covering all nine BMC blocks—customer segments, value propositions, channels, revenue streams, key partners, activities, resources and cost structure—with practical insights, competitive advantages and linked SWOT for investor-ready presentations and strategic decisions.
Customizable Excel Spreadsheet
High-level, editable Business Model Canvas for Atrys that quickly highlights how the company alleviates healthcare and biotech operational pain points—streamlining diagnostics, data services, and patient pathways. Perfect for teams and boards to condense strategy, speed decision-making, and compare business pivots side-by-side.
Activities
Advanced diagnostics operations
Run integrated imaging, pathology and genomics labs under standardized ISO 15189 protocols, with centralized sample logistics and QA to target 24–72 hour diagnostic turnarounds. Maintain external proficiency testing (EQA) and national accreditation programs to ensure traceability and regulatory compliance. Continuously expand and update test menus and digital reporting workflows in 2024 to include novel biomarkers and structured genomic reports.
AI model development and validation
Build and validate algorithms for image analysis, triage, and decision support, following EU MDR and post‑market surveillance requirements in force through 2024 to enable clinical deployment.
Curate governed, labeled datasets with traceability and consent controls, aligning with GDPR and clinical audit standards used across Atrys’ Spain and Latin America operations.
Conduct bias, accuracy, and robustness testing with clinical partners, then deploy models into workflows with continuous monitoring and performance logging for regulatory reporting.
Radiation oncology planning and delivery
Provide comprehensive treatment planning, contouring, and dosimetry services to design patient-specific radiotherapy protocols. Operate linear accelerators and implement QA systems where applicable to ensure delivery accuracy and safety. Integrate multimodality imaging and genomics to personalize dose, fractionation, and target selection. Continuously track outcomes and toxicity metrics to refine protocols and improve quality of care.
Telemedicine and remote monitoring
Atrys delivers virtual consultations, second opinions and scheduled follow-ups while integrating CE-marked remote devices and mobile apps to continuously track vitals and adherence; clinical alerts trigger escalation to in-person care when predefined thresholds are crossed. All communications and data handling comply with GDPR for Spain, ensuring encrypted channels and strict access controls to protect patient privacy.
- Virtual consults, second opinions, follow-ups
- CE-marked devices and apps for vitals/adherence
- Escalation on clinical thresholds
- GDPR-compliant encrypted communication
Regulatory, quality, and data governance
Atrys maintains ISO, CAP, CLIA, MDR and GDPR compliance across operations, implements SOPs, routine audits and incident response, manages consent, de‑identification and data lineage, and reports performance and safety to clinicians and investors; GDPR exposure can be fines up to €20 million or 4% of global turnover, covering ~447 million EU citizens.
- Compliance: ISO, CAP, CLIA, MDR, GDPR
- Controls: SOPs, audits, incident response
- Data: consent, de‑identification, lineage
- Reporting: performance & safety to stakeholders
24–72h ISO 15189 labs, CE/MDR AI imaging, GDPR fines up to €20 million
Operate ISO 15189 labs with centralized logistics targeting 24–72h diagnostics, expand test menus and structured genomic reports in 2024, and maintain EQA accreditation. Develop CE/MDR‑aligned AI for image analysis with continuous post‑market surveillance and clinical monitoring. Deliver radiotherapy planning, remote consults and CE devices with GDPR controls; GDPR fines up to €20 million or 4% turnover covering ~447M EU citizens.
| Metric | 2024 target |
|---|---|
| Turnaround | 24–72h |
Full Version Awaits
Business Model Canvas
The Atrys Business Model Canvas you’re previewing is the actual deliverable, not a mockup or sample. Upon purchase you’ll receive the same complete, editable file formatted exactly as shown, ready for presentation and use. No hidden pages or placeholders—what you see here is what you’ll download and own.
Unlock Healthcare Diagnostics Business Model Canvas — Ready-to-Use Strategic Blueprint
Unlock Atrys’s full Business Model Canvas to see exactly how the company creates value, scales services, and captures healthcare and diagnostics market share. This concise, actionable canvas breaks down customer segments, revenue streams, partnerships and cost structure—ready in Word and Excel. Purchase the complete file for a practical, ready-to-use strategic blueprint ideal for investors, consultants, and founders.
Partnerships
Hospitals and clinics
Partner with public and private hospitals to integrate diagnostics, imaging and oncology workflows, leveraging Atrys networks expanded in 2024 to deepen clinical ties across Spain and Latin America.
Co-develop care pathways and referral protocols to streamline patient intake and reduce delays between diagnosis and treatment.
Enable integrated data exchange with shared quality metrics and support multi-site coverage to ensure continuity of care across hospital networks.
Academic and research institutions
Collaborate with academic and research institutions on clinical trials, genomics research, and validation studies to access novel biomarkers, advanced imaging protocols, and robust evidence generation. Co-author peer-reviewed publications to strengthen clinical credibility and market acceptance. Leverage 2024 research funding streams such as Horizon Europe and institutional grants to subsidize trials and use shared research infrastructure for scale.
Technology and AI vendors
Form alliances with AI, cloud and cybersecurity providers to scale Atrys platforms, tapping a healthcare AI market that surpassed $20B in 2024 and a global cloud services market above $600B. Integrate best-in-class imaging, pathology and genomics algorithms to raise diagnostic accuracy and throughput. Ensure interoperable, regulatory-grade data pipelines to accelerate product roadmaps and cut time-to-market.
Medical device and pharma companies
Atrys partners with medical device and pharma firms to provide companion diagnostics, theranostics, and treatment-planning tools, supporting biomarker-driven patient selection for trials and commercialization; global companion diagnostics market ~6.3 billion USD in 2024. Co-creation of post-market evidence and RWD programs strengthens regulatory positioning and safety signals while joint commercialization expands distribution and revenue reach.
- Companion diagnostics: co-development
- Biomarker-based patient selection: trial enrichment
- RWD/post-market: evidence generation
- Joint commercialization: channel expansion
Payers and health systems
Atrys partners with payers and health systems to align on value-based care and reimbursement pathways, pilot bundled payments for diagnostics and oncology episodes, and share risk through outcome-based contracts tied to clinical benchmarks while integrating services into payer networks and formularies to improve access.
- Value-based alignment
- Bundled diagnostics/onco pilots
- Outcome-based risk sharing
- Payer network integration
Integrate diagnostics, imaging and oncology across Spain & LATAM in 2024
Partner with public/private hospitals to integrate diagnostics, imaging and oncology workflows, leveraging Atrys network expansion in 2024 across Spain and Latin America.
Co-develop care pathways, referral protocols and shared data exchange to shorten diagnosis-to-treatment times and ensure multi-site continuity.
Alliances with AI/cloud/cybersecurity vendors and pharma/device firms accelerate regulatory-grade algorithms and companion diagnostics; healthcare AI market ~$20B (2024), cloud ~$600B (2024), companion dx ~$6.3B (2024).
| Partner | 2024 metric |
|---|---|
| AI market | $20B |
| Cloud market | $600B |
| Companion dx | $6.3B |
What is included in the product
Detailed Word Document
A comprehensive, pre-written Business Model Canvas for Atrys covering all nine BMC blocks—customer segments, value propositions, channels, revenue streams, key partners, activities, resources and cost structure—with practical insights, competitive advantages and linked SWOT for investor-ready presentations and strategic decisions.
Customizable Excel Spreadsheet
High-level, editable Business Model Canvas for Atrys that quickly highlights how the company alleviates healthcare and biotech operational pain points—streamlining diagnostics, data services, and patient pathways. Perfect for teams and boards to condense strategy, speed decision-making, and compare business pivots side-by-side.
Activities
Advanced diagnostics operations
Run integrated imaging, pathology and genomics labs under standardized ISO 15189 protocols, with centralized sample logistics and QA to target 24–72 hour diagnostic turnarounds. Maintain external proficiency testing (EQA) and national accreditation programs to ensure traceability and regulatory compliance. Continuously expand and update test menus and digital reporting workflows in 2024 to include novel biomarkers and structured genomic reports.
AI model development and validation
Build and validate algorithms for image analysis, triage, and decision support, following EU MDR and post‑market surveillance requirements in force through 2024 to enable clinical deployment.
Curate governed, labeled datasets with traceability and consent controls, aligning with GDPR and clinical audit standards used across Atrys’ Spain and Latin America operations.
Conduct bias, accuracy, and robustness testing with clinical partners, then deploy models into workflows with continuous monitoring and performance logging for regulatory reporting.
Radiation oncology planning and delivery
Provide comprehensive treatment planning, contouring, and dosimetry services to design patient-specific radiotherapy protocols. Operate linear accelerators and implement QA systems where applicable to ensure delivery accuracy and safety. Integrate multimodality imaging and genomics to personalize dose, fractionation, and target selection. Continuously track outcomes and toxicity metrics to refine protocols and improve quality of care.
Telemedicine and remote monitoring
Atrys delivers virtual consultations, second opinions and scheduled follow-ups while integrating CE-marked remote devices and mobile apps to continuously track vitals and adherence; clinical alerts trigger escalation to in-person care when predefined thresholds are crossed. All communications and data handling comply with GDPR for Spain, ensuring encrypted channels and strict access controls to protect patient privacy.
- Virtual consults, second opinions, follow-ups
- CE-marked devices and apps for vitals/adherence
- Escalation on clinical thresholds
- GDPR-compliant encrypted communication
Regulatory, quality, and data governance
Atrys maintains ISO, CAP, CLIA, MDR and GDPR compliance across operations, implements SOPs, routine audits and incident response, manages consent, de‑identification and data lineage, and reports performance and safety to clinicians and investors; GDPR exposure can be fines up to €20 million or 4% of global turnover, covering ~447 million EU citizens.
- Compliance: ISO, CAP, CLIA, MDR, GDPR
- Controls: SOPs, audits, incident response
- Data: consent, de‑identification, lineage
- Reporting: performance & safety to stakeholders
24–72h ISO 15189 labs, CE/MDR AI imaging, GDPR fines up to €20 million
Operate ISO 15189 labs with centralized logistics targeting 24–72h diagnostics, expand test menus and structured genomic reports in 2024, and maintain EQA accreditation. Develop CE/MDR‑aligned AI for image analysis with continuous post‑market surveillance and clinical monitoring. Deliver radiotherapy planning, remote consults and CE devices with GDPR controls; GDPR fines up to €20 million or 4% turnover covering ~447M EU citizens.
| Metric | 2024 target |
|---|---|
| Turnaround | 24–72h |
Full Version Awaits
Business Model Canvas
The Atrys Business Model Canvas you’re previewing is the actual deliverable, not a mockup or sample. Upon purchase you’ll receive the same complete, editable file formatted exactly as shown, ready for presentation and use. No hidden pages or placeholders—what you see here is what you’ll download and own.
Original: $10.00
-65%$10.00
$3.50Description
Unlock Healthcare Diagnostics Business Model Canvas — Ready-to-Use Strategic Blueprint
Unlock Atrys’s full Business Model Canvas to see exactly how the company creates value, scales services, and captures healthcare and diagnostics market share. This concise, actionable canvas breaks down customer segments, revenue streams, partnerships and cost structure—ready in Word and Excel. Purchase the complete file for a practical, ready-to-use strategic blueprint ideal for investors, consultants, and founders.
Partnerships
Hospitals and clinics
Partner with public and private hospitals to integrate diagnostics, imaging and oncology workflows, leveraging Atrys networks expanded in 2024 to deepen clinical ties across Spain and Latin America.
Co-develop care pathways and referral protocols to streamline patient intake and reduce delays between diagnosis and treatment.
Enable integrated data exchange with shared quality metrics and support multi-site coverage to ensure continuity of care across hospital networks.
Academic and research institutions
Collaborate with academic and research institutions on clinical trials, genomics research, and validation studies to access novel biomarkers, advanced imaging protocols, and robust evidence generation. Co-author peer-reviewed publications to strengthen clinical credibility and market acceptance. Leverage 2024 research funding streams such as Horizon Europe and institutional grants to subsidize trials and use shared research infrastructure for scale.
Technology and AI vendors
Form alliances with AI, cloud and cybersecurity providers to scale Atrys platforms, tapping a healthcare AI market that surpassed $20B in 2024 and a global cloud services market above $600B. Integrate best-in-class imaging, pathology and genomics algorithms to raise diagnostic accuracy and throughput. Ensure interoperable, regulatory-grade data pipelines to accelerate product roadmaps and cut time-to-market.
Medical device and pharma companies
Atrys partners with medical device and pharma firms to provide companion diagnostics, theranostics, and treatment-planning tools, supporting biomarker-driven patient selection for trials and commercialization; global companion diagnostics market ~6.3 billion USD in 2024. Co-creation of post-market evidence and RWD programs strengthens regulatory positioning and safety signals while joint commercialization expands distribution and revenue reach.
- Companion diagnostics: co-development
- Biomarker-based patient selection: trial enrichment
- RWD/post-market: evidence generation
- Joint commercialization: channel expansion
Payers and health systems
Atrys partners with payers and health systems to align on value-based care and reimbursement pathways, pilot bundled payments for diagnostics and oncology episodes, and share risk through outcome-based contracts tied to clinical benchmarks while integrating services into payer networks and formularies to improve access.
- Value-based alignment
- Bundled diagnostics/onco pilots
- Outcome-based risk sharing
- Payer network integration
Integrate diagnostics, imaging and oncology across Spain & LATAM in 2024
Partner with public/private hospitals to integrate diagnostics, imaging and oncology workflows, leveraging Atrys network expansion in 2024 across Spain and Latin America.
Co-develop care pathways, referral protocols and shared data exchange to shorten diagnosis-to-treatment times and ensure multi-site continuity.
Alliances with AI/cloud/cybersecurity vendors and pharma/device firms accelerate regulatory-grade algorithms and companion diagnostics; healthcare AI market ~$20B (2024), cloud ~$600B (2024), companion dx ~$6.3B (2024).
| Partner | 2024 metric |
|---|---|
| AI market | $20B |
| Cloud market | $600B |
| Companion dx | $6.3B |
What is included in the product
Detailed Word Document
A comprehensive, pre-written Business Model Canvas for Atrys covering all nine BMC blocks—customer segments, value propositions, channels, revenue streams, key partners, activities, resources and cost structure—with practical insights, competitive advantages and linked SWOT for investor-ready presentations and strategic decisions.
Customizable Excel Spreadsheet
High-level, editable Business Model Canvas for Atrys that quickly highlights how the company alleviates healthcare and biotech operational pain points—streamlining diagnostics, data services, and patient pathways. Perfect for teams and boards to condense strategy, speed decision-making, and compare business pivots side-by-side.
Activities
Advanced diagnostics operations
Run integrated imaging, pathology and genomics labs under standardized ISO 15189 protocols, with centralized sample logistics and QA to target 24–72 hour diagnostic turnarounds. Maintain external proficiency testing (EQA) and national accreditation programs to ensure traceability and regulatory compliance. Continuously expand and update test menus and digital reporting workflows in 2024 to include novel biomarkers and structured genomic reports.
AI model development and validation
Build and validate algorithms for image analysis, triage, and decision support, following EU MDR and post‑market surveillance requirements in force through 2024 to enable clinical deployment.
Curate governed, labeled datasets with traceability and consent controls, aligning with GDPR and clinical audit standards used across Atrys’ Spain and Latin America operations.
Conduct bias, accuracy, and robustness testing with clinical partners, then deploy models into workflows with continuous monitoring and performance logging for regulatory reporting.
Radiation oncology planning and delivery
Provide comprehensive treatment planning, contouring, and dosimetry services to design patient-specific radiotherapy protocols. Operate linear accelerators and implement QA systems where applicable to ensure delivery accuracy and safety. Integrate multimodality imaging and genomics to personalize dose, fractionation, and target selection. Continuously track outcomes and toxicity metrics to refine protocols and improve quality of care.
Telemedicine and remote monitoring
Atrys delivers virtual consultations, second opinions and scheduled follow-ups while integrating CE-marked remote devices and mobile apps to continuously track vitals and adherence; clinical alerts trigger escalation to in-person care when predefined thresholds are crossed. All communications and data handling comply with GDPR for Spain, ensuring encrypted channels and strict access controls to protect patient privacy.
- Virtual consults, second opinions, follow-ups
- CE-marked devices and apps for vitals/adherence
- Escalation on clinical thresholds
- GDPR-compliant encrypted communication
Regulatory, quality, and data governance
Atrys maintains ISO, CAP, CLIA, MDR and GDPR compliance across operations, implements SOPs, routine audits and incident response, manages consent, de‑identification and data lineage, and reports performance and safety to clinicians and investors; GDPR exposure can be fines up to €20 million or 4% of global turnover, covering ~447 million EU citizens.
- Compliance: ISO, CAP, CLIA, MDR, GDPR
- Controls: SOPs, audits, incident response
- Data: consent, de‑identification, lineage
- Reporting: performance & safety to stakeholders
24–72h ISO 15189 labs, CE/MDR AI imaging, GDPR fines up to €20 million
Operate ISO 15189 labs with centralized logistics targeting 24–72h diagnostics, expand test menus and structured genomic reports in 2024, and maintain EQA accreditation. Develop CE/MDR‑aligned AI for image analysis with continuous post‑market surveillance and clinical monitoring. Deliver radiotherapy planning, remote consults and CE devices with GDPR controls; GDPR fines up to €20 million or 4% turnover covering ~447M EU citizens.
| Metric | 2024 target |
|---|---|
| Turnaround | 24–72h |
Full Version Awaits
Business Model Canvas
The Atrys Business Model Canvas you’re previewing is the actual deliverable, not a mockup or sample. Upon purchase you’ll receive the same complete, editable file formatted exactly as shown, ready for presentation and use. No hidden pages or placeholders—what you see here is what you’ll download and own.
